Note: Ingredients listed on restricted chemical lists
EC/CAS
7631-86-9
Name of the chemical
Silver adsorbed on silicon dioxide
Concentration
N/A
EC/CAS
532-32-1
Name of the chemical
Benzoic acid and its sodium salt
Concentration
N/A
General Information
Revision date
2022-03-04
Product name
AUGMENTIN 7:1 ORAL SUSPENSION POWDER IN BOTTLE
Product Synonyms
AUGMENTIN DUO 200/28.5 MG/5 ML * AUGMENTIN DUO 400/57 MG/5 ML * AUGMENTIN 200
Emergency telephone
VERISK 3E GLOBAL INCIDENT RESPONSE
Icons in SDS
Company Information
company name
GlaxoSmithKline Canada
e-mail address of the competent person responsible for the Safety Data Sheet
msds@gsk.com
GHS Information
Signal word
Danger
Section 2
Physical hazards
Combustible dusts Category 1
Health hazards
Sensitization, respiratory Category 1 Sensitization, skin Category 1
Environmental hazards
Not classified.
Signal word
Danger
Hazard statements
May form combustible dust concentrations in air. May cause an allergic skin reaction. May cause allergy or asthma symptoms or breathing difficulties if inhaled.
Prevention
Prevent dust accumulation to minimize explosion hazard. Keep away from heat, hot surfaces, sparks, open flames and other ignition sources. No smoking. Keep container tightly closed. Ground and bond container and receiving equipment. Avoid breathing dust. Contaminated work clothing should not be allowed out of the workplace. Wear protective gloves. Wear respiratory protection.
Response
IF INHALED: Remove person to fresh air and keep comfortable for breathing. If skin irritation or rash occurs Get medical advice/attention. If experiencing respiratory symptoms Call a POISON CENTRE/doctor/. Take off contaminated clothing and wash it before reuse. In case of fire: Use appropriate media to extinguish.
Storage
Not available.
Disposal
Dispose of contents/container (in accordance with related regulations).
2.3 Other hazards
This product will support combustion. May form explosible dust-air mixture if dispersed. Caution - Pharmaceutical agent. See section 11 of the SDS for additional information on health hazards.
Additional information
32.52 % of the mixture consists of component(s) of unknown acute oral toxicity. 32.52 % of the mixture consists of component(s) of unknown acute dermal toxicity. 95.71 % of the mixture consists of component(s) of unknown acute inhalation toxicity. 93.85 % of the mixture consists of component(s) of unknown long-term hazards to the aquatic environment.
